Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For more than a decade, we have been at the forefront of groundbreaking #mRNA research that holds immense potential to revolutionize healthcare. Hear more from @cleoabram about how we are studying mRNA to see if one day it can teach our bodies to make its own #medicine. pic.twitter.com/8emxT8yn2P
— Moderna (@moderna_tx) July 19, 2023
Moderna may become a biotech giant by 2030$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
https://www.fool.com/investing/2023/07/19/prediction-company-will-be-a-biotech-giant-by-2030/
we are here to make money!!!!!!!!
Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs
Flagship Pioneering -He is also co-founder and Board Chairman of Moderna.:
Unity is strength$$$$$$$$$
https://www.pfizer.com/news/press-release/press-release-detail/flagship-pioneering-and-pfizer-partner-accelerate
in the end it will be a success---- cancer vaccine!
Merck, Moderna unveil phase 3 trial details for closely watched mRNA cancer vaccine
The vaccine is made by profiling each patient’s tumor mutational signature and is designed to induce an immune response against the corresponding antigens. If eventually successful, Merck and Moderna could open up an entirely new area of cancer treatment.
https://www.fiercebiotech.com/biotech/merck-moderna-post-phase-3-trial-closely-watched-mrna-cancer-vaccine
Moderna: Potential To Get Second Product To Market:
Moderna had $16.3 billion in total assets as of the quarter ending March 31, 2023.
The reason why I believe that its financial position should be strong in 2023 is because it still reiterates that its minimum sales for this period will be about $5 billion, thanks to previously announced Covid-19 vaccine Advanced Purchase Agreements. Not only that, but there is something else to consider as well, which is that it is expecting to negotiate new orders for its Covid-19 vaccine in the fall of 2023. Such negotiations that are taking place for this period are with the U.S., Japan, and Europe.
One thing to note is that should the RSV vaccine mRNA-1345 be approved, sales won't start until at least 2024. Still, this biotech is excellent to look into, because it is expecting six major vaccine launches from its respiratory franchise, with expected annual sales of $8 to $15 billion by 2027. The vaccine franchise that I'm talking about deals with Covid-19, RSV, Flu, and even possibly combinations thereof.
https://seekingalpha.com/article/4615604-moderna-potential-to-get-second-product-to-market
“Any medicines produced under this agreement will be exclusively for the Chinese people — who face many of the same health challenges that affect other communities around the world — and will not be exported,” it said.
The official Xinhua news agency reported that Moderna (MRNA) plans to set up its mRNA pipelines in Shanghai’s Minhang District, adding the pharmaceutical firm will build a production plant.
Moderna agrees deal in China with view to developing mRNA medicines
https://finance.yahoo.com/news/1-moderna-agrees-deal-china-095651433.htm
Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia
The Company has also initiated a rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for mRNA-1345
mRNA-1345 met primary efficacy endpoints, demonstrating vaccine efficacy of 83.7% against RSV lower respiratory tract disease in older adults in the Phase 3 pivotal efficacy trial, ConquerRSV
The Company plans further regulatory submissions for mRNA-1345 worldwide
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Global-Regulatory-Submissions-For-Its-Respiratory-Syncytial-Virus-RSV-Vaccine-MRNA-1345/default.aspx
Moderna to Announce $1 Billion in China Investments, Yicai Says
https://www.bloomberg.com/news/articles/2023-07-04/moderna-to-announce-1-billion-in-china-investments-yicai-says
Revolutionizing Cancer Treatment: The Power of Personalized Vaccines
works in progress
https://scitechdaily.com/revolutionizing-cancer-treatment-the-power-of-personalized-vaccines/
One of the first to receive the ovarian cancer vaccine in a safety study 11 years ago was Jamie Crase of nearby Mercer Island. Diagnosed with advanced ovarian cancer when she was 34, Crase thought she would die young and had made a will that bequeathed a favorite necklace to her best friend. Now 50, she has no sign of cancer and she still wears the necklace.
She doesn't know for sure if the vaccine helped, "But I'm still here."
Vaccines could be the "next big thing" in cancer treatment, scientists say
https://www.cbsnews.com/news/vaccines-cancer-treatment-could-be-next-big-advancement/
Antara Capital LP ownership in NKLA / Nikola Corp
https://fintel.io/so/us/nkla/antara-capital
The next big advance in cancer treatment could be a vaccine
https://apnews.com/article/cancer-vaccines-research-immune-system-c35c8b3003fb75c1a848715a4b4f097f
2023 Anticipated Milestones and Catalysts
Overall response rate and progression-free survival data from phase 2 BRACELET-1 metastatic breast cancer study: Q2 2023
Preclinical data from the combination of pelareorep and CAR T cell therapy: Q2 2023
Updated data in advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) from the GOBLET study: H2 2023
Update on the metastatic colorectal and anal cancer cohorts from the GOBLET study: H2 2023
Guidance for the registration paths for HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC: H2 2023
MODERNA FILES FOR FDA AUTHORIZATION OF ITS UPDATED COVID-19 VACCINE
https://investors.modernatx.com/news/news-details/2023/Moderna-Files-for-FDA-Authorization-of-Its-Updated-COVID-19-Vaccine/default.aspx
Research and development expenses for the first quarter of 2023 increased by 104% to $1.1 billion, in comparison to the same quarter of 2022. The growth in spending was mainly due to an increase in clinical trial-related expenses, largely driven by increased clinical development activities, particularly with respect to the Company's RSV, seasonal flu and CMV programs. The growth was also driven by an increase in personnel-related costs, due to increased headcount to support research and development efforts, and the Company's recently announced collaboration agreements with Life Edit and Generation Bio....
this is called business...for the future!
Two-birds-one-stone approach to combine protein and mRNA vaccines for COVID-19
https://www.nature.com/articles/s41590-023-01539-5
$MRNA
Precision medicine meets cancer vaccines:
https://www.nature.com/articles/s41591-023-02432-2
Experimental vaccine shows promise in delaying the return of aggressive brain tumor...
John Wishman was diagnosed with the deadliest form of brain cancer, glioblastoma, in fall 2020.
Two and a half years later, he’s still traveling and enjoying life — a rarity for a cancer with an average survival time of just 12 to 18 months.
Wishman, 61, of Buffalo, New York, attributes that to an experimental vaccine that’s designed to delay the progression of the tumor
very nice....
https://www.nbcnews.com/health/health-news/brain-tumor-vaccine-experimental-shot-shows-promise-glioblastoma-rcna83362
Moderna’s
Oncology Trials
https://trials.modernatx.com/oncology/
FDA Panel Endorses Updating COVID Jab to Target XBB Strain
On Jun 15, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously recommended updating the COVID vaccines to target the Omicron XBB lineages, which is currently responsible for the majority of the COVID infections in the country.
The VRBPAC voted 21-0 in favor of using a “monovalent” vaccine to target the currently dominating XBB strain, in contrast to the currently available bivalent vaccines that target multiple strains of the coronavirus.
However, the VRBPAC could not reach a decision on which specific XBB lineage should be targeted, nor did it make a recommendation on a vaccination schedule for this newly updated vaccine shot. An FDA official, Dr. Peter Marks, indicated that the FDA may consider selecting the XBB.1.5 subvariant as the preferred target.
The VRCPAC endorsement comes a month after an advisory group to the World Health Organization (“WHO”) recommended the next wave of COVID vaccines to provide protection against the XBB lineages. Earlier this month, the European Medicines Agency also backed WHO’s recommendation. All these agencies observed that though the currently authorized bivalent vaccines provide protection against the XBB lineages, the protection wanes with time.
huge.... Now let's enjoy the ride!
Banned Anti-Vax ‘Menace’ Is Back and Selling ‘Vaccine Cures’ -clown-
https://www.thedailybeast.com/banned-anti-vax-menace-larry-page-is-back-on-elon-musks-twitter-and-selling-vaccine-cures
Moderna is on track to become a multi-product company, and that means it's likely to have many revenue sources down the road.
The company's goal is to capture as much as half of the $30 billion respiratory vaccines market in 2027
next catalyst:
(Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults. Following review by an independent Data and Safety Monitoring Board (DSMB), the primary efficacy endpoints have been met, including vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-associated lower respiratory tract disease (RSV-LRTD) as defined by two or more symptoms. Based on these results, Moderna intends to submit for regulatory approval in the first half of 2023.
Moderna to test mpox vaccine in humans this summer
https://www.fiercebiotech.com/biotech/bio-moderna-test-mpox-vaccine-humans-summer
$RAIN 3.42 in cash per share = MULTIBAGGER$
just waiting for news from Tang. Price will stay in this channel until he is done loading or news breaks on a take over bid.
I don’t see why this man would invest millions & not do nothing. He did a takeover bid in JNCE 3 months ago with fire results for shareholders. Expecting a pop here very soon
last arrived-great signal: https://fintel.io/so/us/rain/tang-capital-partners-lp
deep hands.
Slow and steady! a potential game changer for so many patients! The treatment still has a ways to go but the interim data has been incredible!
This is just a waste of time! adios
we have two different ideas!
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
https://meetings.asco.org/abstracts-presentations/218505
go back to the cave!
your words mean nothing
Moderna said during its investor call that it was starting a Phase 3 confirmatory study, which it hoped to open in the third quarter of this year.
Scientists have been chasing the dream of vaccines to treat cancer for decades with few successes. Experts say mRNA vaccines, which can be produced in as little as eight weeks, paired with drugs that rev up the immune system may lead to a new generation of cancer therapies--------
cancer- mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65%
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
Adverse events reported with mRNA-4157 (V940) in KEYNOTE-942 were consistent with those previously observed in a Phase 1 clinical trial. The safety profile of KEYTRUDA was consistent with findings from previous studies. The number of patients reporting treatment related Grade = 3 adverse events were similar between the arms (25% vs 18%, respectively). The most common adverse events of any grade attributed to either mRNA-4157 (V940) or the combination of mRNA-4157 (V940) and KEYTRUDA were fatigue (60.6%), injection site pain (55.8%) and chills (50.0%).
https://investors.modernatx.com/news/news-details/2023/Moderna-and-Merck-Announce-mRNA-4157-V940-in-Combination-With-KEYTRUDAR-pembrolizumab-Demonstrated-a-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-F/default.aspx
Tang bought 30% of the float...